Pharmacyclics Inc

Pharmacyclics — Technical Presentation (June 2013)

19 slides from Pharmacyclics's technical presentation, Jun 17, 2013

  1. Slide 1: Disclosures

    Disclosures SIMON RULE, MD Johnson & Johnson (Research Funding, Scientific Advisory Board); Celgene (Research Funding, Scientific Advisory Board); GSK (Research Funding); Pharmacyclics (Scientific Advisory Board); Napp (Scientific Advisory Board); Roche (Scientific Advisory Board)

  2. Slide 2: Updated Interim Results of Phase 2 Study of Ibrutinib in R/R MCL

    Updated Interim Results of an International, Multicenter, Phase 2 Study of Ibrutinib (PCI-32765) in Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL) Simon Rule?, Michael L. Wang?, Peter Martin, Rebecca Auer‘, Brad S. Kahl’, Wojciech Jurczak®, Ranjana H. Advani’, Jorge Romaguera’, Michael Will

  3. Slide 3: Bruton's Tyrosine Kinase (BTK): A Critical Kinase for Lymphoma Cell Survival

    Bruton’s Tyrosine Kinase (BTK): A Critical Kinase for Lymphoma Cell Survival and Proliferation ‘Chemokine-controlled cell migration + Bruton’s tyrosine kinase (BTK) is an essential element of the BCR signaling pathway (Niiro, NRI 2002) + Inhibitors of BTK block BCR signaling and induce apoptosis, +

  4. Slide 4: Ibrutinib

    LP Ibrutinib

  5. Slide 5: Study Design

    Study Design * International, multicenter, open-label, phase II single-agent study of ibrutinib in patients with relapsed or refractory MCL ° Treatment: 560 mg oral ibrutinib daily until progression or unacceptable toxicity * Conducted at 18 sites (9 US and 9 EU) * Data cut on Dec 26, 2012 ° Patient

  6. Slide 6: Objectives

    Objectives ¢ Primary objectives: — Overall response rate (ORR) ¢ Secondary objectives: — Duration of response (DOR), progression-free survival (PFS), overall survival (OS), and safety/tolerability © Two cohorts enrolled in parallel without randomization: — Bortezomib-naive (65 patients) * No prior b

  7. Slide 7: Patient Eligibility

    Patient Eligibility * Confirmed MCL, with cyclin D1+, or t(11;14), and measurable disease + Failure to achieve at least partial response (PR) to, or disease progression after, most recent treatment regimen * Atleast 1, but not > 5 prior lines of therapy for MCL * Adequate end-organ function — ANC2 0

  8. Slide 8: Patient Characteristics

    Patient Characteristics For All Treated Population Bortezomib-Naive _Bortezomib-Exposed Total (n=63) (N=48) (N= 211) Median Age, yrs (Range) 66 (46-83) 69 (40-84) 68 (40-84) Gender: Male 46 (73%) 39 (81%) 85 (77%) ECOG Status: o-2 53 (84%) 46 (96%) 99 (89%) 2 9 (14%) 2(4%) 11 (10%) >2 1 (2%) 0 (0%)

  9. Slide 9: Disease History

    Disease History For All Treated Population Bortezomib-Naive Bortezomib-Exposed _Total (N = 63) (N = 48) (N= 111) Prior high intensity therapy Hyper CVAD 18 (29%) 15 (31%) 33 (30%) Stem cell transplant 8 (13%) 4 (8%) 12 (11%) Prior lenalidomide 9 (14%) 18 (38%) 27 (24%) MIPI Score Intermediate risk 2

  10. Slide 10: Treatment Emergent AEs in > 15% of Patients

    Treatment Emergent AEs in > 15% of Patients Regardless of Relationship to Study Therapy Hematological AE — 10% 20% 30% 40% Non-Hematological AE Dlarrhea| Fatigue Nausea edema peripheral Pyrexia Abdominal pain Rash] x 30% 40% 50%

  11. Slide 11: Maximum Percent Decrease of Lymph Node Sum of Perpendicular Diameters

    Maximum Percent Decrease of Lymph Node Sum of Perpendicular Diameters (SPD) For All Treated Population* 150 I Bortezomib-Naive (N= 56) I Bortezomib-Exposed (N = 47) 50. 50 -100 103 of 111 pts had baseline and post-baseline PD measurements,

  12. Slide 12: Best Response

    Best Response #00 cr PR 80 ™ 68 67 68 x 60 a g 4 S é 20 19 ° Bortezomib- Bortezomib- Total Naive Exposed (n= 111) (n=63) (n= 48) * Efficacy Population n= 111, Estimated Median Follow-up 15.3 months

  13. Slide 13: Improvement of Complete and Overall Response Rates Over Time

    Improvement of Complete and Overall Response Rates Over Time 100 5 cR 90 | MPR 80 4 x 70 gs % 60 « g 50 2 g 40 3 2 30 20 10 Time, months

  14. Slide 14: Response to Ibrutinib is Independent of Patient Characteristics and Risk Factors

    Response to ibrutinib is Independent of Patient Characteristics and Risk Factors ALL subjects bea a Aeoiyes) Severn =) ‘ Comore BOM i= ® sx roy % Priornumberot Regimens SS pig Ee Simpttios mit seoro_ meme ik (45) ==! 7 sesatnetcos we s 22 -——— 2 Advanced oiseae YO wo a ies ree zsem he a blanc Holy S

  15. Slide 15: Kaplan-Meier Duration of Response

    Kaplan-Meier Duration of Response (n=75) 100: rtezomib-Exposed ® reronb he : Comored S E = 60 3 a a = mumor at Soneanisatie 5 20-4 » 2 s : ° 4g 7 peueomi tuosed Au ol’ * ” x ‘ ° 3 qt 3 2 ra 2 Months From First Response © Estimated median DOR was 17.5 months (95%CI: 15.8, NE) * For patients with best

  16. Slide 16: Kaplan-Meier Progression-Free Survival

    Kaplan-Meier Progression-Free Survival (n=111) Progression-Free Survival, % Months From First Dose Estimated Median PFS (Cl 95%) 13.9 months (7.0, NE)

  17. Slide 17: Kaplan-Meier Overall Survival

    Kaplan-Meier Overall Survival (n=111) 100 —a Coneconibexponed Borteromb- Naive + Conorea 80 x 3 60 z = 0 6 Number at se |Bortezomib-Nsive Sertexoni-txpssd rs ‘3 » a B ‘ ° jal odin 2 x 2 2 s ° 0 H 3 2 16 20 2a Months From First Dose * Estimated Median OS was not reached + Estimated OS of 58% at 18 mo

  18. Slide 18: Conclusions

    Conclusions ¢ Ibrutinib demonstrated unprecedented single agent ORR in relapsed or refractory MCL — Responses have been durable — Magnitude of response (CR) improved with longer follow-up — Responses independent of baseline patient characteristics, prior treatments, and risk factors e Ibrutinib has

  19. Slide 19: Acknowledgements

    Acknowledgements ¢ All of the patients and their families who participated in this trial e Investigators and clinical research staff from all participating centers e Pharmacyclics staff

Pharmacyclics — Technical Presentation (June 2013) on 6ix